Brokerages Set Tourmaline Bio, Inc. (NASDAQ:TRML) Price Target at $54.00

Tourmaline Bio, Inc. (NASDAQ:TRMLGet Free Report) has earned a consensus rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $54.00.

A number of equities research analysts have weighed in on TRML shares. Guggenheim reissued a “buy” rating on shares of Tourmaline Bio in a report on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and set a $49.00 target price on shares of Tourmaline Bio in a research note on Wednesday, December 11th. BMO Capital Markets began coverage on shares of Tourmaline Bio in a research report on Friday, December 6th. They issued an “outperform” rating and a $50.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of Tourmaline Bio in a research report on Wednesday, December 11th.

Get Our Latest Research Report on TRML

Hedge Funds Weigh In On Tourmaline Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. acquired a new stake in shares of Tourmaline Bio during the 3rd quarter valued at $8,701,000. Blue Owl Capital Holdings LP boosted its position in Tourmaline Bio by 18.5% during the second quarter. Blue Owl Capital Holdings LP now owns 1,715,401 shares of the company’s stock valued at $22,060,000 after purchasing an additional 268,000 shares during the last quarter. State Street Corp grew its stake in Tourmaline Bio by 25.6% in the third quarter. State Street Corp now owns 411,980 shares of the company’s stock valued at $10,592,000 after purchasing an additional 83,949 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Tourmaline Bio by 184.9% in the 2nd quarter. Renaissance Technologies LLC now owns 100,076 shares of the company’s stock valued at $1,287,000 after buying an additional 64,950 shares in the last quarter. Finally, Acuta Capital Partners LLC grew its stake in shares of Tourmaline Bio by 23.2% in the 3rd quarter. Acuta Capital Partners LLC now owns 332,095 shares of the company’s stock valued at $8,538,000 after buying an additional 62,481 shares in the last quarter. Institutional investors and hedge funds own 91.89% of the company’s stock.

Tourmaline Bio Stock Down 3.1 %

Shares of TRML opened at $17.00 on Friday. The firm has a market capitalization of $435.88 million, a PE ratio of -6.03 and a beta of 2.36. The firm has a 50-day moving average price of $21.52 and a 200 day moving average price of $21.12. Tourmaline Bio has a 52-week low of $12.12 and a 52-week high of $48.31.

Tourmaline Bio (NASDAQ:TRMLGet Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.06. On average, equities analysts expect that Tourmaline Bio will post -2.99 EPS for the current year.

About Tourmaline Bio

(Get Free Report

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

Read More

Analyst Recommendations for Tourmaline Bio (NASDAQ:TRML)

Receive News & Ratings for Tourmaline Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tourmaline Bio and related companies with MarketBeat.com's FREE daily email newsletter.